Ultima Genomics and Exact Sciences Enter Long-Term Supply Agreement to Improve Patient Access to Genomic Testing by Lowering Sequencing Costs

NEWARK, Calif. and MADISON, Wis., June 21, 2022 /PRNewswire/ — Ultima Genomics, Inc. and Exact Sciences Corporation (Nasdaq: EXAS) have entered into a long-term supply agreement for Ultima’s next-generation sequencing (NGS) technologies. Under the terms of the supply agreement, Ultima Genomics will provide access to its NGS products, which are based on a novel architecture designed to enable sequencing at a fraction of the cost of other commercially available technologies. The companies also plan to develop one or more of Exact Sciences’ advanced cancer diagnostic tests using Ultima’s sequencing technology. In conjunction with this agreement, Exact Sciences became an investor in Ultima and joined its ongoing early access program for its high-throughput NGS instrument platform, the UG 100™. The collaboration aims to reduce the high cost of sequencing to improve patient access to genomic testing and human health.

Photo credit: Ultima Genomics (PRNewsfoto/Ultima Genomics)

“Exact Sciences believes that access to differentiated and affordable genomics technologies is essential to provide patients with better information before diagnosis and at all stages of cancer treatment,” said Kevin Conroy, Chairman and CEO of Exact Sciences. “Ultima’s mission to reduce the cost of sequencing and increase the use of genomic information supports our goal of providing accurate and affordable testing options across the cancer continuum. This is particularly important for applications such as cancer screening, minimal residual disease and recurrence monitoring, which could lead to millions of tests per year.”

“We founded Ultima Genomics with a mission to continuously drive genomic information to scale. We believe our mission is closely aligned with our customers’ goals, and we look forward to enabling Exact Sciences and other d ‘perform sequencing at a fraction of the cost today,” said Gilad Almogy, CEO of Ultima Genomics. “We have designed our new sequencing architecture to go beyond conventional technologies, and we are excited to bring it to market soon. the UG 100™, our first instrument using this architecture, for a greater number of customers. Going forward, we aim to continually improve our technology, reduce costs, and scale genomic information to improve patient outcomes. »

Over the past 5 years, Ultima Genomics has developed a fundamentally new sequencing architecture designed to go beyond conventional approaches, including completely different flow cell engineering and sequencing chemistry, and machine learning. Ultima is currently participating in an early access program for the UG 100™, its first high-throughput NGS instrument using this new technology architecture.

About Ultima Genomics

Ultima Genomics unlocks the power of genomics at scale. The company’s mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. As humanity stands on the cusp of a biological revolution, there is a virtually endless need for additional genomic information to cope with the complexity and dynamic change of biology, as well as an additional need to challenge the next-generation conventional sequencing technologies. Ultima’s revolutionary new sequencing architecture reduces sequencing costs to help overcome the trade-offs scientists and clinicians are forced to make between the breadth, depth, and frequency with which they use genomic information. The new sequencing architecture was designed to scale far beyond conventional sequencing technologies, reduce the cost of genomic information, and catalyze the next phase of genomics in the 21st century. To learn more, visit www.ultimagenomics.com

About the exact sciences

A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions that provide the clarity needed to take life-changing action, sooner. Building on the success of the Cologuard and Oncotype tests, Exact Sciences is investing in its product portfolio to support patients before and throughout their cancer diagnosis and treatment. Exact Sciences brings together visionary collaborators to advance the fight against cancer. For more information, please visit the company’s website at www.exactsciences.comfollow Exact Sciences on Twitter @ExactScienceswhere to find Exact Sciences on Facebook.

Exact Sciences forward-looking statements

This press release contains forward-looking statements regarding our expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on assumptions made by the management of Exact Sciences as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions and events to differ materially from those anticipated. . There can be no assurance that Exact Sciences will enter into a development agreement with Ultima, use Ultima’s products or services in Exact Sciences’ current or future tests, or successfully develop, launch, or commercialize additional tests. Accordingly, you should not place undue reliance on forward-looking statements. Risks and uncertainties that could affect Exact Sciences’ forward-looking statements are described in the Risk Factors sections of Exact Sciences’ most recent Annual Report on Form 10-K and all subsequent Quarterly Reports on Form 10-Q, as well as than in its other reports filed with the Securities and Exchange Commission. Exact Sciences disclaims any obligation to publicly update any forward-looking statements, written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Ultimate contact: [email protected]
Exact Sciences investor contact: Megan Jones, [email protected]608-535-8815
Exact sciences media contact: Stephanie Spanos, [email protected], 608-800-6648

Photo credit: Exact Sciences

Photo credit: Exact Sciences

Quote

Quote

Show original content to download multimedia:https://www.prnewswire.com/news-releases/ultima-genomics-and-exact-sciences-enter-long-term-supply-agreement-aimed-at-improving-patient-access-to-genomic-testing- by-reducing-the-costs-of-sequencing-301571749.html

SOURCE Ultima Genomics; Exact Sciences

Michael J. Chiaramonte